Yuri Rukazenkov

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +15

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert et al. · Journal of Clinical Oncology · 2011 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +17

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer

Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2018 · 789 citations · Full text

Medicine, Oncology, Pharmacology +17